Kairos Discovery
Biotech company (Lyon, France) developing next-generation targeted cancer therapies focused on kinase biology. The organization applies medicinal chemistry, structural biology and PK/PD-guided optimization to generate selective small-molecule therapeutics and protein degraders, advancing preclinical candidates toward IND-enabling studies and early clinical development. Founded in 2022 and supported by public grants and private investors, the company emphasizes translational oncology, biomarker-guided strategies, and preclinical evaluation in disease-relevant models.
Industries
Nr. of Employees
small (1-50)
Kairos Discovery
Products
Bivalent small-molecule CK2 inhibitor (lead preclinical candidate)
Preclinical bivalent small-molecule inhibitor designed to engage both the ATP-binding site and a neighboring allosteric pocket of a serine/threonine kinase to achieve sustained, selective functional blockade and tumor-selective cytotoxicity.
CDK-targeted protein degrader programs (preclinical)
Preclinical programs developing protein degraders aimed at cyclin-dependent kinases to remove target proteins and modulate non-catalytic functions implicated in cancer.
KDX350
A bivalent CK2ɑ inhibitor designed to engage both the ATP-binding pocket and a neighboring allosteric site on the CK2α subunit for solid tumors.
Bivalent CK2α inhibitor
A next-generation targeted therapy designed to overcome the limitations of conventional kinase inhibition by targeting CK2α.
CDK-targeted protein degrader
A next-generation modality designed to target cyclin-dependent kinases via targeted protein degradation.
KDXXX
CDK degraders pipeline program for targeted protein degradation in oncology.
Bivalent small-molecule CK2 inhibitor (lead preclinical candidate)
Preclinical bivalent small-molecule inhibitor designed to engage both the ATP-binding site and a neighboring allosteric pocket of a serine/threonine kinase to achieve sustained, selective functional blockade and tumor-selective cytotoxicity.
CDK-targeted protein degrader programs (preclinical)
Preclinical programs developing protein degraders aimed at cyclin-dependent kinases to remove target proteins and modulate non-catalytic functions implicated in cancer.
KDX350
A bivalent CK2ɑ inhibitor designed to engage both the ATP-binding pocket and a neighboring allosteric site on the CK2α subunit for solid tumors.
Bivalent CK2α inhibitor
A next-generation targeted therapy designed to overcome the limitations of conventional kinase inhibition by targeting CK2α.
CDK-targeted protein degrader
A next-generation modality designed to target cyclin-dependent kinases via targeted protein degradation.
KDXXX
CDK degraders pipeline program for targeted protein degradation in oncology.
Expertise Areas
- Precision oncology
- Medicinal chemistry
- Small-molecule drug discovery
- Protein degrader (targeted degradation) development
Key Technologies
- Bivalent small-molecule inhibitor design
- Targeted protein degraders (PROTAC-like modalities)
- Structural biology
- PK/PD optimization
News & Updates
Article describing the role of medicinal chemistry in designing compounds that target specific molecular pathways and translating research into therapeutic candidates.
Discussion of challenges with traditional kinase inhibitors (short-lived efficacy, adverse effects) and approaches to address them.
Overview of bivalent inhibitors, their mechanism of binding two sites to increase selectivity and potential therapeutic advantages.
Educational article on the role of a serine/threonine kinase in tumor development and rationale for prioritizing it in drug development.
Discussion of therapeutic strategies that target kinase functions beyond catalytic inhibition to improve outcomes in precision oncology.
Scientific inception and recognition including French Tech Seed label and preclinical proof-of-concept through incubation within Pulsalys.
Article describing the role of medicinal chemistry in designing compounds that target specific molecular pathways and translating research into therapeutic candidates.
Discussion of challenges with traditional kinase inhibitors (short-lived efficacy, adverse effects) and approaches to address them.
Overview of bivalent inhibitors, their mechanism of binding two sites to increase selectivity and potential therapeutic advantages.
Educational article on the role of a serine/threonine kinase in tumor development and rationale for prioritizing it in drug development.
Discussion of therapeutic strategies that target kinase functions beyond catalytic inhibition to improve outcomes in precision oncology.
Scientific inception and recognition including French Tech Seed label and preclinical proof-of-concept through incubation within Pulsalys.